{Reference Type}: Journal Article
{Title}: Real-world evidence of sotrovimab effectiveness for preventing severe outcomes in patients with COVID-19: A quality improvement propensity-matched retrospective cohort study of a pan-provincial program in Alberta, Canada.
{Author}: Farmer G;Sikdar KC;Lo T;Conly J;Slobodan J;Ross J;James S;Usman H;Kemp K;Baker K;Doucette K;Nijssen-Jordan C;Saxinger LM;Joffe AM;
{Journal}: Int J Infect Dis
{Volume}: 146
{Issue}: 0
{Year}: 2024 Jun 14
{Factor}: 12.074
{DOI}: 10.1016/j.ijid.2024.107136
{Abstract}: <B>OBJECTIVE: </B>Post-marketing surveillance of sotrovimab's effect during implementation in the Canadian population is limited.<BR><B>METHODS: </B>The study used a propensity score-matched retrospective cohort design. Follow-up began between the periods of December 15, 2021 and April 30 2022. The study assessed any severe outcome defined as all-cause hospital admission or mortality within 30 days of a confirmed COVID-19-positive test. Covariate-adjusted odds ratios between sotrovimab treatment and the severe outcome was conducted using logistic regression.<BR><B>RESULTS: </B>There were 22,289 individuals meeting the treatment criteria for sotrovimab. There were 1603 treated and 6299 untreated individuals included in the analysis. The outcome occurrence in the study was 5.49% (treated) and 4.21% (untreated), with a median time from diagnosis to treatment of 1.00 days (interquartile range 2.00 days). In the propensity-matched cohort, sotrovimab was not associated with lower odds of a severe outcome (odds ratio 1.20, 95% confidence interval 0.91-1.58), adjusting for confounding variables.<BR><B>CONCLUSIONS: </B>After adjusting for confounding variables, sotrovimab treatment was not associated with lower odds of a severe outcome within 30-days of COVID-19-positive date.